Stay updated on PembROlizuMab vs Chemo in MPM Clinical Trial
Sign up to get notified when there's something new on the PembROlizuMab vs Chemo in MPM Clinical Trial page.

Latest updates to the PembROlizuMab vs Chemo in MPM Clinical Trial page
- Check5 days agoChange DetectedThe clinical trial record for the PROMISE-meso study is displayed in place of an access error, providing details about pembrolizumab versus standard chemotherapy for advanced malignant pleural mesothelioma.SummaryDifference61%

- Check12 days agoChange DetectedThe footer revision label changed from v3.7.2 to v3.8.0 on the page displaying a 403 Forbidden error.SummaryDifference0.2%

- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedA site-wide NIH announcement about terminology during a transition appears above the page, and the displayed site revision changes from v3.7.1 to v3.7.2.SummaryDifference1%

- Check40 days agoChange DetectedThe footer’s site revision identifier changed from v3.7.0 to v3.7.1, while the page still shows a 403 Forbidden error.SummaryDifference0.2%

- Check47 days agoChange DetectedThe 403 Forbidden page content and the Home link were removed from the page. This eliminates the error-state text that previously appeared when access was denied.SummaryDifference0.5%

- Check54 days agoChange DetectedThe study details page now displays a 403 Forbidden page instead of the study content. This blocks access to the study overview, documents, locations, and related resources.SummaryDifference19%

Stay in the know with updates to PembROlizuMab vs Chemo in MPM Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PembROlizuMab vs Chemo in MPM Clinical Trial page.